← Back to Search

PD-L1 Inhibitor

Durvalumab and focal radiotherapy for Ovarian Cancer

Phase 1
Waitlist Available
Research Sponsored by British Columbia Cancer Agency
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up from date of study enrollment until confirmed ca-125 progression, through study completion, an average of 1 year
Awards & highlights

Study Summary

It is postulated that focal sensitizing radiotherapy may potentiate the effectiveness of durvalumab. The purpose of this study is to test the safety and tolerability of 2 different dose levels of focal sensitizing radiation therapy given with durvalumab.

Eligible Conditions
  • Ovarian Cancer
  • Peritoneal Carcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~from date of study enrollment until confirmed ca-125 progression, through study completion, an average of 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and from date of study enrollment until confirmed ca-125 progression, through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Determine the maximum tolerated dose of durvalumab combined with focal irradiation for use in recurrent ovarian cancer
Secondary outcome measures
CA-125 response rate
Immune-related response rate
Objective response rate
Other outcome measures
Survival

Trial Design

1Treatment groups
Experimental Treatment
Group I: Durvalumab and focal radiotherapyExperimental Treatment2 Interventions
Durvalumab 1500 mg IV every 28 days, and 2 fractions of focal sensitizing radiation with cycles 1 and 2 of treatment.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Durvalumab
FDA approved
Focal radiotherapy
1999
Completed Phase 3
~320

Find a Location

Who is running the clinical trial?

British Columbia Cancer AgencyLead Sponsor
171 Previous Clinical Trials
90,489 Total Patients Enrolled
5 Trials studying Ovarian Cancer
349 Patients Enrolled for Ovarian Cancer
Ozmosis Research Inc.Industry Sponsor
20 Previous Clinical Trials
4,993 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.
Anna Tinker 2018. "PDL-1 Inhibition and Focal Sensitizing Radiotherapy in Recurrent Ovarian/Primary Peritoneal/Fallopian Tube Cancers.". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03283943.
All > Fallopian Tube Cancer
~3 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top